Vesugen — originating-institute clinical report
Comparison in people
- What was studied
- 40 patients with atherosclerosis, ages 54–77. Vesugen plus conventional care: 25. Conventional care: 15. Enrollment ran from November 2005 to February 2006.
- Main finding
- In a 40-patient report, mean post-treatment total cholesterol was 6.4 mmol/L with Vesugen plus conventional care and 7.0 mmol/L with conventional care alone. The report gives one shared baseline column.
Total cholesterol, mmol/L · 8.2 ± 0.3 before treatment. 6.4 ± 0.3 with Vesugen plus usual care and 7.0 ± 0.2 with usual care at follow-up. · p<0.05 vs the single reported baseline value for both post-treatment columns. No between-group test is shown.
Reported findings and study design
Comparative institutional report from St. Petersburg. Investigators assessed symptoms and used blood lipid testing, routine blood and urine tests, and coagulation measures.
Population or model 40 patients with atherosclerosis, ages 54–77. Vesugen plus conventional care: 25. Conventional care: 15. Enrollment ran from November 2005 to February 2006.
Dose, route and schedule
In the study, participants took 1–2 oral capsules 2–3 times daily, 10–15 minutes before meals, over 10–15 days. The clinical methods do not specify the mass of peptide per capsule.
Protocol source ↗ · Originating institute report, clinical methods and Tables 1–2
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Total cholesterol, mmol/L | 8.2 ± 0.3 before treatment. 6.4 ± 0.3 with Vesugen plus usual care and 7.0 ± 0.2 with usual care at follow-up. | p<0.05 vs the single reported baseline value for both post-treatment columns. No between-group test is shown. |
| Very-low-density lipoproteins, mmol/L | 1.23 ± 0.05 at baseline. 0.96 ± 0.05 with Vesugen plus usual care and 1.08 ± 0.04 with usual care at follow-up. | |
| Triglycerides, mmol/L | 4.5 ± 0.2 at baseline. 4.1 ± 0.2 with Vesugen plus usual care and 4.2 ± 0.7 with usual care at follow-up. |
Table 2 gives a single pretreatment column. The report does not document blinded allocation or a between-group efficacy estimate, and it provides no long-term vascular outcomes.
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- Commercially distributed institute report; independent peer review, randomization and blinding not established.
- Product composition is not independently characterized here; do not equate a marketed formulation with a purified experimental sequence.
- Reported absence of harms does not establish safety.
Source details
Institute report / commercial reproduction
Originating institute report, clinical methods and Tables 1–2
Sources checked
Citation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Originating institute; report reproduced in commercial collection. Vesugen — originating-institute clinical report Reports on clinical studies of CYTOMAX and CYTOGEN products; PDF page 101